人多发性骨髓瘤细胞RPMI-8226

细胞名称

人多发性骨髓瘤细胞RPMI-8226                  

货物编码

BFN608006107

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研用途     3类

培养体系

DMEM高糖培养基（Hyclone）+10%胎牛血清（Gibco）+1%双抗（Hyclone）

培养温度

37℃

二氧化碳浓度

5%

简介

人多发性骨髓瘤细胞RPMI-8226细胞来源于一位61岁的男性浆细胞瘤患者；可产生免疫球蛋白轻链，未检测到重链。 

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Part of: NCI-7 clinical proteomics reference material cell line panel.

Characteristics: Produces IgG lambda.

Doubling time: 60 hours (PubMed=25984343); 33.5 hours (NCI-DTP); ~60-70 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.

Misspelling: RPMI-8266; Occasionally.

Misspelling: RPMI-8826; In Cosmic 875867.

Derived from sampling site: Peripheral blood.

STR信息

Amelogenin：X，Y；CSF1PO：12；D13S317：11；D16S539：9；D18S51：15，19；D19S433：13.2，14；D21S11：28，29；D2S1338：20；D3S1358：16，17；D5S818：11，13；D7S820：9，10；D8S1179：12，13；FGA：19；TH01：8；TPOX：8，11；vWA：16，18；

参考文献

PubMed=6042436; DOI=10.3181/00379727-125-32327

Matsuoka Y., Moore G.E., Yagi Y., Pressman D.

Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.

Proc. Soc. Exp. Biol. Med. 125:1246-1250(1967)

PubMed=4177524

Matsuoka Y., Takahashi M., Yagi Y., Moore G.E., Pressman D.

Synthesis and secretion of immunoglobulins by established cell lines of human hematopoietic origin.

J. Immunol. 101:1111-1120(1968)

PubMed=5243066

Moore G.E., Kitamura H.

Cell line derived from patient with myeloma.

N. Y. State J. Med. 68:2054-2060(1968)

PubMed=18605421; DOI=10.1093/jnci/45.5.951

Ikeuchi T., Sandberg A.A.

Chromosome pulverization in virus-induced heterokaryons of mammalian cells from different species.

J. Natl. Cancer Inst. 45:951-963(1970)

DOI=10.1016/B978-0-12-427150-0.50135-2

Matsuoka Y.

Immunoglobulins.

(In) Tissue culture. Methods and applications; Kruse P.F. Jr., Patterson M.K. Jr. (eds); pp.599-607, Academic Press; New York (1973)

PubMed=4366935

Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.

The presence of the Epstein-Barr viral genome in human lymphoblastoid B-cell lines and its absence in a myeloma cell line.

Cancer Res. 34:1898-1903(1974)

DOI=10.1007/978-1-4757-1647-4_11

Moore G.E.

Cell lines from humans with hematopoietic malignancies.

(In) Human tumor cells in vitro; Fogh J. (eds.); pp.299-331; Springer; New York (1975)

PubMed=3893568

Goldstein M., Hoxie J., Zembryki D., Matthews D., Levinson A.I.

Phenotypic and functional analysis of B cell lines from patients with multiple myeloma.

Blood 66:444-446(1985)

PubMed=2537114

Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M., Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M., Bataille R.

Phenotypic analysis of human myeloma cell lines.

Blood 73:566-572(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x

Nakano A., Harada T., Morikawa S., Kato Y.

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

CLPUB00447

Mulivor R.A., Suchy S.F.

1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.

(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

PubMed=8943038; DOI=10.1073/pnas.93.24.13931

Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x

Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5

Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H., Bast B.J.E.G.

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.

Cancer Genet. Cytogenet. 109:99-107(1999)

PubMed=10557056; DOI=10.1038/sj.leu.2401563

Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.

Detection of MUM1/IRF4-IgH fusion in multiple myeloma.

Leukemia 13:1812-1816(1999)

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x

Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M.

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Br. J. Haematol. 107:392-395(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Leuk. Res. 24:681-703(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=11154231; DOI=10.1182ood.v97.2.516

Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A.

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

Blood 97:516-522(2001)

PubMed=11157491; DOI=10.1182ood.V97.3.729

Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Blood 97:729-736(2001)

PubMed=12068308; DOI=10.1038/nature00766

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=14555701

Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Mol. Cancer Ther. 2:825-833(2003)

PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2

Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S., Taniwaki M., Inazawa J.

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Am. J. Pathol. 165:71-81(2004)

PubMed=15748285; DOI=10.1186/1479-5876-3-11

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11-11(2005)

PubMed=16956823

Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.

The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.

Haematologica 91:1234-1240(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433

Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17171682; DOI=10.1002/gcc.20404

Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Genes Chromosomes Cancer 46:226-238(2007)

PubMed=18277095; DOI=10.4161/cbt.7.5.5712

Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

Cancer Biol. Ther. 7:699-708(2008)

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

Characterization of MYC translocations in multiple myeloma cell lines.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

PubMed=18700954; DOI=10.1186/1755-8794-1-37

Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Deliliers G.L., Neri A.

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

BMC Med. Genomics 1:37-37(2008)

PubMed=19306352; DOI=10.1002/gcc.20660

Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A., Todoerti K., Ronchetti D., Deliliers G.L., Neri A.

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Genes Chromosomes Cancer 48:521-531(2009)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21173094; DOI=10.3324/haematol.2010.033456

Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Haematologica 96:574-582(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23074853; DOI=10.1134/S1990519X12050136

Turilova V.K., Smirnova T.D.

Karyotypic variability of human myeloma cell lines.

Tsitologiia 54:621-636(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25688540; DOI=10.1002to.a.22643

Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P., Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A., Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Cytometry A 87:285-288(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165

Clark D.J., Hu Y., Bocik W., Chen L., Schnaubelt M., Roberts R., Shah P., Whiteley G., Zhang H.

Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.

J. Proteome Res. 17:2205-2215(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31465861; DOI=10.1016/j.jprot.2019.103504

Chanukuppa V., Paul D., Taunk K., Chatterjee T., Sharma S., Kumar S., Santra M.K., Rapole S.

XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach.

J. Proteomics 209:103504-103504(2019)